Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data.

CONCLUSIONS: Patients with biochemical persistence after RP are approximately 2.5 times more likely to experience local/metastatic failure and death, compared to patients with biochemical recurrence after RP, despite equivalent sRT with/without antiandrogen therapy use. These data may facilitate patient counseling and shared treatment selection. PMID: 32229186 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32229186?dopt=Abstract

Source: Urologic Oncology - March 26, 2020 Category: Urology & Nephrology Authors: Sood A, Keeley J, Palma-Zamora I, Arora S, Dalela D, Olson P, Hanna R, Cotter D, Jeong W, Elshaikh M, Rogers CG, Peabody JO, Menon M, Abdollah F Tags: Urol Oncol Source Type: research